Anthracyclines-Induced Cardiac Dysfunction: What Every Clinician Should Know.

Area of Science:

• Oncology
• Cardiology
• Pharmacology

Background:

• Chemotherapies have significantly improved cancer patient survival over the past two decades.
• However, chemotherapy agents, particularly anthracyclines, can cause severe adverse effects, including cardiotoxicity.
• Anthracycline-induced cardiotoxicity can lead to heart failure, limiting treatment efficacy and patient outcomes.

Purpose of the Study:

• To review current evidence on anthracycline cardiotoxicity.
• To explore the classification and molecular mechanisms of anthracycline-induced heart damage.
• To provide an overview of diagnostic, therapeutic, and preventive strategies for managing cardiotoxicity.

Main Methods:

• Literature review of existing studies on anthracyclines and cardiotoxicity.
• Analysis of data regarding molecular mechanisms, diagnosis, and management.
• Synthesis of current evidence on prevention and treatment approaches.

Main Results:

• Anthracyclines are associated with significant cardiac risks, including heart failure.
• Understanding the molecular pathways is crucial for identifying at-risk patients.
• Early diagnosis and proactive management are key to mitigating cardiovascular damage.

Conclusions:

• Prompt identification and management of anthracycline cardiotoxicity are essential.
• Effective strategies can prevent treatment discontinuation and improve patient survival.
• Managing cardiotoxicity enhances both short-term and long-term cardiovascular health in cancer patients.